RIGL
Rigel Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow +26.6% ·
net new positions +16.7%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 535.68K | $25.79M | +1 | n/a |
| Q2 2026 | 72 | -2 | 9.47M | $370.29M | +3 | −5 |
| Q1 2026 | 77 | -10 | 11.13M | $301.00M | n/a | −10 |
| Q4 2025 | 86 | +1 | 11.49M | $491.92M | +1 | n/a |
| Q3 2025 | 18 | +3 | 6.87M | $194.53M | +3 | n/a |
| Q2 2025 | 12 | +2 | 4.47M | $83.70M | +2 | n/a |
| Q1 2025 | 7 | -1 | 1.55M | $27.81M | +2 | −3 |
| Q4 2024 | 8 | +4 | 1.41M | $23.66M | +5 | −1 |
| Q3 2024 | 3 | -2 | 554.02K | $8.97M | n/a | −2 |
| Q2 2024 | 5 | n/a | 605.71K | $4.98M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 1.72M | +6.1% | $48.87M | 0.0% | ▲ Add | 2 | SEC ↗ ×10 |
| 2 | The Vanguard Group ✦ (passive) | 1.04M | -0.9% | $29.55M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 3 | Goldman Sachs Group ✦ | 737.03K | n/a | $20.88M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Marshall Wace ✦ | 601.33K | +63.0% | $17.04M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 554.32K | -7.6% | $15.70M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 474.21K | +100.6% | $13.43M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 423.72K | +1.9% | $12.01M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | D. E. Shaw & Co. ✦ | 306.49K | New | $8.68M | 0.0% | New | 1 | SEC ↗ ×2 |
| 9 | Two Sigma Investments ✦ | 220.30K | +474.6% | $6.24M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Arrowstreet Capital ✦ | 186.33K | +747.6% | $5.28M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Morgan Stanley ✦ | 146.27K | n/a | $4.14M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 12 | Millennium Management ✦ | 105.30K | +236.9% | $2.98M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 86.46K | New | $2.45M | 0.0% | New | 1 | SEC ↗ ×2 |
| 14 | JPMorgan Chase ✦ | 69.92K | n/a | $1.98M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 15 | Wellington Management ✦ | 61.77K | -3.2% | $1.75M | 0.0% | ▼ Trim | 4 | SEC ↗ ×3 |
| 16 | Fidelity (FMR) ✦ | 59.09K | +1641.4% | $1.67M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 17 | AQR Capital Management ✦ | 56.60K | +463.9% | $1.60M | 0.0% | ▲ Add | 3 | SEC ↗ ×5 |
| 18 | T. Rowe Price ✦ | 9.29K | New | $264,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| D. E. Shaw & Co. | $8.68M | 0.0% |
| Citadel Advisors | $2.45M | 0.0% |
| T. Rowe Price | $264,000 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 146 holders, 15.81M shares, $391.97M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.